HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief executive officer, David Arthur, will be attending the 30^th Annual Oppenheimer Healthcare Conference being held in New York City.

Details of the conference are as follows:

Event: Oppenheimer 30^th Annual Healthcare Conference
Dates: Tuesday, March 17, 2020 and Wednesday, March 18, 2020
Format: One-on-One Meetings 
Location: InterContinental New York Barclay Hotel, 111 E. 48^th St., New York, NY

The Oppenheimer Healthcare Conference brings together a broad spectrum of public and private healthcare companies, spanning all major sectors of the healthcare sector. Attendees will have the opportunity to interact with more than 180 company management teams and gain insight from key thought leaders on a variety of topical issues. Mr. Arthur will provide a corporate update highlighting recent achievements, upcoming clinical milestones and its focus on developing epigenetic-based therapies for rare and hard-to-treat cancers. Analysts and investors interested in arranging a meeting should contact Jeremy Feffer at LifeSci Advisors, LLC (contact info below).

Salarius’ clinical development pipeline is led by Seclidemstat, a potent reversible inhibitor of the LSD1 enzyme. Seclidemstat is already the subject of a Phase 1/2 study in Ewing sarcoma, a rare pediatric bone cancer, for which it has been granted Fast Track Designation by the FDA, as well as Orphan and Rare Pediatric Disease designations. A second Phase 1/2 study is also underway in advanced solid tumors (AST), including prostate, breast and ovarian cancers. Last year, Salarius achieved important dose escalation and trial enrollment events for each trial, positioning the company to report early patient data from both clinical trials in 2020.

About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius is also developing Seclidemstat for a number of cancers, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “could,” “believe,” “plan,” “expect,” “target,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding Salarius’ clinical development pipeline, the status of the Phase 1/2 studies for Seclidemstat in Ewing sarcoma and advanced solid tumors, that Salarius is positioned to report early patient data from clinical trials in 2020,and the potential of Seclidemstat as a potent reversible inhibitor of the LSD1 enzyme. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of Salarius to raise additional capital to meet its business operational needs and to achieve its business objectives and strategy; Salarius’ ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius’ cash resources; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Investor Relations
LifeSci Advisors, LLC
Jeremy Feffer
Managing Director
(212) 915-2568 
jeremy@lifesciadvisors.com

Media Relations
Tiberend Strategic Advisors, Inc.
Johanna Bennett
Senior Vice President
(212) 375-2686 
jbennett@tiberend.com

Source: Salarius Pharmaceuticals